List view / Grid view

Articles

 

Neuronal morphology screening as a tool in neuroscience drug discovery

27 March 2007 | By Myles Fennell and John Dunlop, Neuroscience Discovery Research, Wyeth Research

High content screening (HCS) has now become integrated into all aspects of drug discovery from target identification and validation to hit generation and lead optimisation through to toxicological profiling. In neuroscience, the ability to perform automated neurite outgrowth and neuronal morphology screening has been a significant driver of HCS implementation.…

Novel strategies for antidepressant drug discovery

27 March 2007 | By Chad E. Beyer, PhD, Discovery Neuroscience, Wyeth Research

Despite marked advances in our understanding of chemical transmission, many of the complex processes, namely, our appreciation of the varying roles of neurochemicals in disease etiology, are still being investigated. To aid in this exploration and to monitor the extracellular levels of neurochemicals in living tissue systems, techniques such as…

HTS technologies to facilitate chemical genomics

27 March 2007 | By Douglas S. Auld, James Inglese, Ajit Jadhav and Christopher P. Austin, NIH Chemical Genomics Center, National Institutes of Health, Bethesda, G.Sitta Sittampalam, Chahrzad Montrose-Rafizadeh and James E. Mcgee, Lead Generation & Lead Optimization Biology, Discovery Chemistry Research & Technology and Philip W. Iversen, Global Discovery & Development Statistics, Eli Lilly & Company

Industrial scale technologies developed and applied within the pharmaceutical industry for the purpose of drug discovery have recently been adopted by many research laboratories for the purpose of facilitating chemical genomics. Taking full advantage of these technologies will require education in high-throughput screening assay systems as well as new methods…

Industry Insight: United they stand

27 March 2007 | By EPR

Late last year, Thermo Electron and Fisher Scientific merged to become Thermo Fisher Scientific, Inc., the world leader in serving science. European Pharmaceutical Review spoke to Marc Casper, vice president of Thermo Fisher Scientific and president of its analytical technologies group to discover the impact this has had on the…

Calorimetry for polymorph detection

27 March 2007 | By Simon Gaisford PhD., School of Pharmacy, University of London and Michael AA O’Neill PhD., Department of Pharmacy and Pharmacology, University of Bath

Characterising the properties of a material, understanding how these properties change in relation to local environment and quantifying potential interactions with other species are facets central to any drug development programme. Not understanding and, more importantly, not controlling these factors can have serious consequences for a pharmaceutical, from irreproducible processing…

PAT and scalable automation for bioprocess control and monitoring

27 March 2007 | By Joydeep Ganguly, PAT Group Lead and Gerrit Vogel, Senior Engineering Manager, Talecris Biotherapeutics

This case study provides a comprehensive look at Talecris1 Biotherapeutics’ approach to PAT and automation followed by examples of PAT deployed on a bioprocess. It introduces the concept of integrated and scalable automation, provides a comparison of automation concepts and explains how the selected automation effectively supports initiatives such as…

Advancing the science of drug discovery

27 March 2007 | By EPR

Montréal, one of Canada’s most vibrant and beautiful cities, provides an idyllic setting for the Society of Biomolecular Sciences’ 13th Annual Conference & Exhibition. The 2007 scientific program encompasses many of the core themes from previous SBS conferences, including target biology and screening strategies, as well as new instrumentation and…

Cleanroom standards

27 March 2007 | By John Neiger, Technical writer and consultant

It is some years since the ISO 14644 and 14698 series of international cleanroom standards started taking over from national standards. Early parts are already undergoing their statutory five-year reviews; other parts have only recently been published and new parts are still being written.

Taking clinical trials into the future

27 March 2007 | By EPR

Q1: Please outline the general process of Phase I clinical trials. Burnand: Phase I is the screening for safety process and it’s the first time that a product is given to a human being. The aim at this stage is to demonstrate that the product isn’t dangerous. The data will…

A new challenge in the pharmaceutical supply chain

27 March 2007 | By Montanari R. and Rizzi A., Dipartimento di Ingegneria Industriale, Università degli Studi di Parma

Current trends show that the Radiofrequency Identification (RFID) technology and Electronic Product Code (EPC) are experiencing increasing diffusion. Several business applications adopting RFID are currently expected to grow strongly. Bar codes and RFID will coexist for many years, although the former is likely to progressively replace the latter in some…

Cancer immunotherapy using RNAi

25 January 2007 | By Chih-Ping Mao, Department of Pathology, Chien-Fu Hung, Ph.D, Department of Pathology and Oncology and T-C Wu, Ph.D., Department of Pathology, Oncology, Obstetrics and Gynecology and Molecular Microbiology and Immunology, Johns Hopkins Medical Institutions

Immunotherapy has recently emerged as an attractive form of treatment for cancer due to the potential of the immune system to eradicate tumours without inflicting damage on normal tissue. However, natural immune responses are usually inadequate to control cancer progression and require enhancement by vaccines.

A new field in biomarker discovery and target identification

25 January 2007 | By Dr. Ina K. Dahlsveen, Exiqon

The last few years have seen a rush of discoveries within a new field of post-transcriptional gene regulation. microRNAs, or miRNAs for short, are small regulating RNAs akin to small interfering RNAs (siRNA), but which are naturally expressed in vivo. Originally discovered in C. elegans 14 years ago, these small…

The role of phospho-proteomics in drug discovery and development

25 January 2007 | By Ze’ev Gechtman, Ph.D., formerly of Johnson & Johnson

While scientific discoveries can be turned into financial assets, the scientific process itself has proven difficult to harness to efficiently create marketed products bringing profits. This translation is especially challenging for the pharmaceutical and biotechnology industries owing to the tremendous complexity of biological systems.

Send this to a friend